Research You Can Use

Esketamine for Treatment-Resistant Depression — First FDA-Approved Antidepressant in a New Class

Treating major depressive disorder remains an important challenge worldwide. The disorder impairs productivity, social functioning, and overall health, reducing life expectancy and burdening health care systems.1 Although many treatments exist, at least a third of patients do not have a response after two or more trials of antidepressant drugs and are considered to have treatment-resistant depression.2 Such

Esketamine for Treatment-Resistant Depression — First FDA-Approved Antidepressant in a New Class Read More »

Conditional probabilities of substance use disorders and associated risk factors

Progression from first use to use disorder on alcohol, cannabis, stimulants, sedatives and opioids Highlights Pre-existing mental disorders increases the risk of developing SUD. Prior SUD increases the risk of transitioning from use to use disorder. Highest rates of transition to SUD occurred among stimulant and opioid users. Mood and anxiety disorders increased the risk of transitioning to AUD

Conditional probabilities of substance use disorders and associated risk factors Read More »

Scroll to Top